Micromet to Provide Update on BiTE Antibody R&D Programs at 2010 American Society of Hematology Annual Meeting

Micromet, Inc. (NASDAQ:MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on two of its BiTE antibody development programs will be reported at the 52^nd Annual American Society of Hematology Annual Meeting, to be held December 4 – 7 in Orlando, Florida.

Accepted abstracts include:

Abstract #: 174
First author: Max Topp, MD, University of Wuerzburg, Wuerzburg, Germany
Oral presentation: Monday, December 6, 8:15 AM ET
Location: Room 311 ABCD
Investigators will present long-term efficacy and safety data from a phase 2 trial of the Company’s lead product candidate blinatumomab in patients with MRD-positive acute lymphoblastic leukemia (ALL). Earlier results from this trial provided the basis for a pivotal trial now enrolling at leading cancer centers worldwide.

Abstract #: 14
First author: Michael Aigner, PhD, University Hospital of Erlangen, Erlangen, Germany
Oral presentation: Sunday, December 5, 4:45 PM
Location: Room 311 ABCD
Investigators will report for the first time on the activity of the Company’s CD33 BiTE antibody against human cancer cell lines.

Abstract #: 2880
First author: Andreas Viardot, MD, University Hospital Ulm, Ulm, Germany
Poster presentation: Sunday, December 5, 6 – 8 PM ET
Location: Hall A3/A4, poster board #: II-760
Investigators will present updated results from an on-going phase 1 trial of blinatumomab in patients with relapsed non-Hodgkin's lymphoma (NHL). Long-term efficacy and safety data on indolent lymphoma patients will be reported along with initial data on patients with aggressive NHLs.

Abstracts can be found at www.hematology.org.

About Blinatumomab

Blinatumomab (MT103) is a next-generation monoclonal antibody designed to direct the body's cell destroying T-cells against CD19, a protein expressed on the surface of B-cell derived acute lymphoblastic leukemias and non Hodgkin's lymphomas. Micromet has received orphan drug designation from the European Medicines Agency for blinatumomab for the treatment of acute lymphoblastic leukemia, mantle cell lymphoma and chronic lymphatic leukemia and from the U.S. Food and Drug Administration for the treatment of acute lymphoblastic leukemia, chronic lymphocytic leukemia and indolent B cell lymphoma.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. The Company’s lead product candidate blinatumomab (MT103) is currently the subject of a European pivotal trial in patients with minimal residual disease positive acute lymphoblastic leukemia. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including Bayer Schering Pharma, Boehringer Ingelheim, MedImmune, Merck Serono, Nycomed and sanofi-aventis. Additional information can be found at www.micromet.com.